VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
HLNHaleon plc
$8.96$39.9B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksHLNP/E History

HLN logoHaleon plc (HLN) P/E Ratio History

Fairly Valued

Trading at 18.7x, near 5Y avg of 20.0x · 57th percentile · In line with own history · Data 2022–2025

Current P/E (TTM)
18.7x
-7% vs 5Y avg
5Y Avg P/E
20.0x
Median 17.9x
5Y Percentile
57th
Mid-range
PEG Ratio
2.22
Premium to growth
5-Year P/E Range
18.7x
Min14.7xMedian17.9xMax28.6x
TTM EPS$0.70
Price$8.96
Earnings Yield5.34%
EPS Growth (1Y)12.5%
EPS Growth (5Y)8.4%

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Haleon plc (HLN) trades at a price-to-earnings ratio of 18.7x, with a stock price of $8.96 and trailing twelve-month earnings per share of $0.70.

The current P/E is roughly in line with its 5-year average of 20.0x. Over the past five years, HLN's P/E has ranged from a low of 14.7x to a high of 28.6x, placing the current valuation at the 57th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, HLN trades at a 15% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

The PEG ratio of 2.22 (P/E divided by 13% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, HLN trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HLN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

HLN Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
18.7vs22.1
-15%
Below Sector
vs. S&P 500
18.7vs24.4
-23%
Below Market
PEG Analysis
2.22
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 13% EPS growth (1Y)

HLN P/E vs Peers

Consumer health and OTC self-care peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
KVUE logoKVUEKenvue Inc.
$35B23.8-+41%
CHD logoCHDChurch & Dwight Co., Inc.
$23B31.7-+27%
PG logoPGThe Procter & Gamble Company
$351B23.14.13+8%
CL logoCLColgate-Palmolive Company
$72B34.0--25%
PBH logoPBHPrestige Consumer Healthcare Inc.
$2B12.03.19-9%
JNJ logoJNJJohnson & Johnson
$550B39.4--58%
NVS logoNVSNovartis AG
$281B20.51.33+22%
GSK logoGSKGSK plc
$102B6.9Lowest0.48Best+348%Best
MCK logoMCKMcKesson Corporation
$90B19.6-+49%
CAH logoCAHCardinal Health, Inc.
$52B34.4-+87%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

HLN Historical P/E Data (2022–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Dec 31 2025$10.11$0.6914.7x-27%
FY2025 Q2Jun 30 2025$10.37$0.5817.9x-11%
FY2024 Q4-$9.54$0.5517.4x-13%
FY2024 Q2Jun 30 2024$8.26$0.4617.8x-11%
FY2023 Q4Dec 31 2023$8.23$0.3821.8x+9%
FY2023 Q2Jun 30 2023$8.38$0.3822.1x+10%
FY2022 Q4Dec 31 2022$8.00$0.2828.6x+43%

Average P/E for displayed period: 20.0x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into HLN consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

4+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HLN — Frequently Asked Questions

Quick answers to the most common questions about buying HLN stock.

What is HLN's P/E ratio?

Haleon plc (HLN) trailing twelve-month P/E ratio is 18.7x, based on TTM diluted EPS of $0.70. The 5-year average P/E is 20.0x and the historical range spans 14.7x to 28.6x.

Is HLN stock overvalued or undervalued?

HLN trades at 18.7x P/E, near its 5-year average of 20.0x. The 57th percentile ranking within the 14.7x–28.6x historical range places valuation within normal bounds.

Is HLN stock expensive?

HLN is fairly valued relative to its own history. The current P/E of 18.7x is near the 5-year average of 20.0x (57th percentile of historical range).

What is HLN's historical P/E range?

Over the past 5 years, HLN's P/E ratio has ranged from 14.7x to 28.6x, with a median of 17.9x and an average of 20.0x. The current P/E of 18.7x places the stock at the 57th percentile of this range. Full historical data spans 2022–2025.

How does HLN's P/E compare to the S&P 500?

HLN trades at 18.7x P/E versus the S&P 500 median of 24.4x. The 23% discount to the market suggests lower growth expectations or perceived higher risk.

How does HLN's valuation compare to Healthcare peers?

Haleon plc P/E of 18.7x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is HLN's PEG ratio?

HLN PEG ratio is 2.22, based on a P/E of 18.7x and EPS growth of 12.5%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.

What is HLN's earnings yield?

HLN earnings yield is 5.34%, the inverse of its 18.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

HLN P/E Ratio History (2022–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current14.7x
Period Avg20.0x
Range14.7x - 28.6x
Change-49%
7 quartersDec 31, 2022 - Dec 31, 2025